Relapsing-Remitting Multiple Sclerosis clinical trials at University of California Health
9 in progress, 3 open to eligible people
Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
open to eligible people ages 18-50
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated…
at UCLA
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
open to eligible people ages 18-55
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative…
at UCSF
Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
open to eligible people ages 18-65
B cell-depleting therapies, such as ocrelizumab, are among the most effective medications currently available for the treatment of multiple sclerosis (MS). This suggests that B cells play a very important role in MS. While B cells are rapidly…
at UCSF
Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sorry, in progress, not accepting new patients
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration. The double-blind period will last…
at UCSD UCSF
BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Sorry, in progress, not accepting new patients
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with…
at UCSD
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
Sorry, in progress, not accepting new patients
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance …
at UCSF
Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis
Sorry, in progress, not accepting new patients
In this Phase 1b open-label prospective clinical trial, patients with relapsing-remitting MS will undergo FMT of FMP30 (donor stool) via colonoscopy and immunological efficacy endpoints will be assessed at various time points. The active phase of…
at UCSF
Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Sorry, not currently recruiting here
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
at UCSF
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sorry, in progress, not accepting new patients
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early…
at UCLA UCSD UCSF
Our lead scientists for Relapsing-Remitting Multiple Sclerosis research studies include Bijal Mehta Sabatino, Jr., Joseph Jeffrey Gelfand Ari Green Riley Bove.
Last updated: